Earnings Insights · BNTX · Q3 FY2026

BioNTech Q3 2026 Earnings: BMS Collaboration Revenue Lifts Quarter as Oncology Pipeline Takes Center Stage

By AlgovestIQ ResearchPublished

Share

Key earnings findings

BioNTech (BNTX) Q3 FY2026 · results discussed on the earnings call

  1. BioNTech reported Q3 FY2026 revenue of $1.46B against the $1.17B analyst estimate, a 24.8% beat, and EPS of $0.83 against the $0.76 analyst estimate, a 9.2% beat.
  2. BNTX closed at $86.92 on Nov 3, 2026, down 0.7% from $87.53 on Nov 2, 2026, the last close before the results were released.
  3. BioNTech reported third-quarter revenue of €1.3B, down from €1.5B a year earlier as COVID-19 vaccine demand continued to decline.

Sources: the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did BioNTech beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$1.46B
$1.17B
+24.8%
EPS
$0.83
$0.76
+9.2%
  • Revenue surprise across the last 8 reported quarters has ranged from -34.2% to 110.9%.

Reported figures against analyst estimates, compiled from AlgovestIQ data, in U.S. dollars. The company reports in another currency, so the article's figures differ.

BioNTech reported third-quarter revenue of €1.3B, down from €1.5B a year earlier as COVID-19 vaccine demand continued to decline. The quarter was supported by €613M of revenue recognized from its partnership with Bristol Myers Squibb on pumitamig, underscoring that current revenue remains heavily influenced by collaboration economics rather than a broad commercial oncology base.

The central investment story is BioNTech’s effort to convert its large post-pandemic cash position into oncology approvals. Clinical progress in lung cancer was encouraging, but several important programs remain early, pivotal readouts are years away, and the company disclosed setbacks or more limited prospects in parts of its mRNA and ADC portfolios.

As Reported on the Call

MetricReportedChange
Q3 revenue€1.3BDown from €1.5B
Revenue from BMS pumitamig partnership€613MN/A
Year-to-date revenue€1.5BDown from €2B
Q3 adjusted R&D expense€579MUp from €479M
Q3 IFRS R&D expense€748MN/A
Q3 adjusted and IFRS SG&A expense€179MUp from €149M
Year-to-date adjusted R&D expense€1.6BUp from €1.5B
Year-to-date adjusted SG&A expense€527MUp from €407M
Cash equivalents and security investments€16.2BN/A
Shares repurchased through September 30Approximately 5 millionN/A
Full-year 2026 revenue guidance€1.7B to €1.9BMidpoint raised
Full-year adjusted R&D guidance€2B to €2.3BUnchanged
Full-year adjusted SG&A guidance€700M to €800MUnchanged

The Bigger Story

BioNTech is increasingly positioning pumitamig, its PD-L1/VEGF-A bispecific antibody developed with Bristol Myers Squibb, as the potential backbone of a broader oncology combination strategy. Management is testing it with chemotherapy, antibody-drug conjugates, and mRNA immunotherapies across lung, breast, gastrointestinal, and genitourinary cancers.

That strategy gained support from early-stage data in small-cell lung cancer and metastatic triple-negative breast cancer. However, the company is still deciding which combinations and indications to advance into registrational studies. Most of the clinical data discussed were from early-stage, signal-seeking trials rather than confirmatory studies.

The nearer-term pivotal opportunity is gotistobart in second-line squamous non-small cell lung cancer. Updated data from the non-pivotal portion of its global Phase III program showed median overall survival of 18.5 months, versus 10 months for docetaxel, with a hazard ratio of 0.56. The pivotal portion of the study is ongoing, with an initial interim analysis expected before year-end.

The first interim analysis is explicitly early. Management said it would not view the absence of a clear signal at that point as a disappointment, making the next planned interim analysis in 2027 potentially more consequential.

Revenue and Operating Performance

Third-quarter revenue fell 13% year over year to €1.3B, primarily reflecting lower anticipated demand for BioNTech’s COVID-19 vaccine. The company’s revenue base remains in transition as vaccine sales decline from pandemic-era levels and the oncology pipeline has yet to generate product revenue.

The most important contributor to quarterly revenue was €613M recognized from the global partnership with Bristol Myers Squibb for pumitamig. The payment provides substantial near-term support, but it should not be treated as recurring commercial revenue from an approved oncology product.

Year-to-date revenue was €1.5B, down from €2B in the first nine months of 2025. The difference between the quarter and year-to-date figures reflects the concentration of partnership-related revenue recognition in the third quarter.

BioNTech raised the midpoint of its 2026 revenue outlook following the quarter, suggesting the partnership revenue and quarterly performance tracked ahead of its previous internal expectations. Still, management’s guidance range remains below the company’s historical COVID-vaccine revenue levels, reinforcing the importance of pipeline execution.

Profitability and Margins

BioNTech continued to direct substantial capital toward late-stage oncology development. Adjusted R&D expense increased 21% year over year to €579M in the third quarter, driven by greater investment in prioritized immuno-oncology and ADC programs.

IFRS R&D expense was €748M, including €169M of impairment losses related to intangible assets outside the company’s strategic focus. The impairment indicates continued portfolio rationalization as BioNTech concentrates capital on programs it considers more likely to create value.

SG&A expense rose to €179M from €149M. Management attributed the increase to pre-launch activities for late-stage programs, commercial infrastructure buildout, and broader process and enterprise-resource-planning investments. These expenditures show BioNTech is preparing for potential oncology launches, but they also increase the company’s fixed-cost base before product revenue has materialized.

The company said it is offsetting some of this investment through pipeline prioritization, manufacturing consolidation, and broader cost discipline. It also divested the JPT Peptide Technologies business and plans to integrate artificial intelligence subsidiary InstaDeep more directly into BioNTech’s core operations.

Demand, Customers and Pricing

The key commercial demand trend remains the expected decline in COVID-19 vaccine demand. BioNTech did not frame the vaccine business as a renewed growth driver, instead emphasizing its transition toward a multi-product oncology company by 2030.

Clinical demand and competitive positioning are more relevant to the current thesis. In lung cancer, BioNTech is developing pumitamig across several registrational programs and is evaluating combinations with ADCs intended to reduce reliance on chemotherapy over time.

Early data for pumitamig plus Alpha-D, a B7-H3-targeted ADC, were notable but preliminary. Among 71 small-cell lung cancer patients across four dose levels, management reported overall response rates of 92% in first-line treatment, 76% in second line, and 52% in third line and later. The combination showed a 2.9% interstitial lung disease rate, with no dose-limiting toxicities reported.

The data support further development, but BioNTech has not yet selected a specific indication, trial design, or timeline for a pivotal pumitamig-plus-Alpha-D program. Management expects to provide more detail on its 2027 milestones in coming months.

In metastatic triple-negative breast cancer, BioNTech is adapting its ROSETTA Breast-01 trial as treatment standards evolve. The company plans, subject to regulatory clearance, to replace chemotherapy with Gilead’s TROP2-targeted ADC sacituzumab govitecan in the study. The change is strategically sensible given the changing treatment landscape, but it also means the trial is being adjusted before it can establish a definitive path to registration.

What is BioNTech’s guidance for full-year 2026?

BioNTech raised its full-year 2026 revenue guidance to €1.7B to €1.9B. The company said the higher midpoint reflects its third-quarter revenue performance.

Management maintained its adjusted R&D expense guidance of €2B to €2.3B and adjusted SG&A guidance of €700M to €800M. The outlook points to continued elevated spending as the company advances multiple Phase III programs and prepares commercial infrastructure for potential oncology launches.

For the pipeline, the most immediate clinical milestone is the first interim analysis of the gotistobart Phase III trial in squamous non-small cell lung cancer before year-end. Management said it will comment on the result whether the independent monitoring committee recommends unblinding the study or continuing to the next planned analysis.

BioNTech has seven global pivotal pumitamig studies underway by the end of 2026. Management said the studies are event-driven, limiting its ability to provide firm readout timing. Based on currently listed primary completion dates, it expects China data in first-line triple-negative breast cancer in 2027, followed by ROSETTA Lung-02 and ROSETTA Lung-01 around 2029.

Balance Sheet, Cash Flow and Capital

BioNTech ended the third quarter with €16.2B in cash equivalents and security investments, giving it substantial flexibility to fund clinical development, partnerships, and selective business development without an immediate financing need.

The company repurchased approximately 5 million shares from the June launch of its buyback program through September 30. The repurchases signal management’s willingness to return some capital while preserving the financial capacity to fund its oncology strategy.

BioNTech also exercised an option in its Roche/Genentech collaboration that will shift future R&D costs for the mRNA cancer immunotherapy program to Roche/Genentech beginning January 1. BioNTech will remain eligible for royalties and retain transitional supply responsibilities.

Management characterized the change as a capital-allocation decision rather than a reduced commitment to mRNA cancer vaccines. Economically, the move lowers BioNTech’s future cost burden on the program while reducing its direct participation in cost and profit sharing.

The clinical picture for mRNA remains mixed. BioNTech and Genentech discontinued an adjuvant colorectal cancer trial of autogene cevumeran after an independent monitoring board identified a numerical overall-survival imbalance between treatment arms and concluded the study was unlikely to change its efficacy outcome. Meanwhile, the pancreatic cancer study continues, with enrollment completed.

BNT113 also missed its first dual primary endpoint of progression-free survival in first-line HPV16-positive head and neck cancer. The Phase II/III study continues to its overall-survival endpoint, which could still establish a positive outcome under the trial design if statistically significant.

What Investors Should Watch

1. Gotistobart’s Year-End Interim Analysis

The pivotal trial in second-line squamous non-small cell lung cancer is BioNTech’s most important near-term efficacy event. The strong non-pivotal survival data create meaningful expectations, but the early timing of the first interim means a continuation decision may be more likely than an unblinding.

2. Pumitamig’s Move From Early Signals to Registrational Trials

Pumitamig combinations have generated encouraging response-rate data, particularly in small-cell lung cancer and triple-negative breast cancer. Investors should watch which ADC combinations BioNTech selects for pivotal development and whether early activity translates into durable benefit and acceptable safety in larger studies.

3. The Economics and Quality of Revenue

The BMS partnership contributed €613M in quarterly revenue, helping BioNTech raise its full-year revenue outlook. Future quarters will need to show how much revenue comes from vaccine demand, collaboration accounting, and eventually product sales, rather than one-time or milestone-based contributions.

4. mRNA Cancer Vaccine Readouts

The colorectal discontinuation and missed BNT113 progression-free-survival endpoint have increased the importance of overall-survival data in head and neck cancer and the continuing pancreatic cancer study. These programs will determine whether mRNA remains a differentiated oncology pillar or becomes a more selective investment area.

5. ADC Portfolio Prioritization

T-Pam met its primary endpoint in HR-positive, HER2-low metastatic breast cancer, but management described the progression-free-survival improvement as modest and said the potential patient benefit appeared limited in the current treatment landscape. Decisions on a potential biologics license application and broader development plans will clarify the asset’s commercial role.

AlgovestIQ Takeaway

BioNTech’s quarter was financially supported by partnership revenue while the underlying operating story remained a transition away from COVID-19 vaccines and toward oncology. The €613M contribution from Bristol Myers Squibb was meaningful, but it also highlights that the company has not yet replaced vaccine revenue with recurring sales from an internally developed oncology product.

The pipeline has produced some encouraging signals. Gotistobart’s non-pivotal survival data in squamous lung cancer stand out as the most clinically mature opportunity, while pumitamig is developing into a broad combination platform with several potential routes to registration. The strength of the early response data in small-cell lung cancer is notable, but it requires confirmation in larger, controlled trials.

At the same time, the quarter exposed the uneven nature of drug development. The colorectal cancer vaccine program was discontinued, BNT113 missed its progression-free-survival endpoint, and T-Pam’s breast cancer benefit was characterized as modest despite meeting its primary endpoint. These outcomes reinforce the need to distinguish pipeline breadth from de-risked commercial opportunity.

BioNTech’s €16.2B cash position remains a major strategic advantage. It can support late-stage development, absorb setbacks, pursue partnerships, and return capital to shareholders. The shift in the Roche/Genentech collaboration also demonstrates greater financial discipline as pipeline spending expands.

The central investment question is whether BioNTech can turn its substantial clinical portfolio and capital base into one or more commercially meaningful oncology launches before its COVID-19 business declines further. Confirmation of gotistobart’s survival benefit, clearer pumitamig pivotal-development decisions, and durable efficacy data from the mRNA programs would strengthen that case. Further clinical setbacks or prolonged timelines to registrational readouts would leave the company more dependent on its balance sheet and collaboration revenue.

How did BNTX stock react?

BNTX closed at $86.92 on Nov 3, 2026, down 0.7% from $87.53 on Nov 2, 2026, the last close before the results were released.

SessionCloseChange
Nov 2, 2026 (before release)$87.53—
Nov 3, 2026$86.92-0.7%
Nov 4, 2026$90.70+3.6%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Reported results, segment revenue, margins, cash flow and guidance quoted in this article. Source: BioNTech SE Q3 FY2026 earnings call transcript, as of Nov 3, 2026.
  2. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 3, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.